SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

GUJARAT TERCE LABORATORIES

BSE: 524314 29 Jun 2025
Healthcare
₹ 54.01
Gujarat Terce Laboratories Ltd specializes in Pharmaceuticals within the Healthcare sector.

GUJARAT TERCE LABORATORIES - Share Price & Details

Market Cap
₹42.8
High /Low
94.9 / 44.5
Stock P/E
NA
Book Value
₹8.73
Dividend Yield
0.0
ROCE
41.5
ROE
₹-14.4
Face Value
10.0
PEG Ratio
NA
EVEBITDA
₹10.2
Debt
0.94
CMP / FCF
21.7
Debt to equity
₹0.15
NP Ann
-0.98
High price all time
94.9
Piotroski score
₹7.0
Graham Number
NA
No. Eq. Shares
0.74
Net CF
₹0.69
Net profit
-0.98
Price to book value
6.61
Interest Coverage
₹9.1
Low price all time
3.91
Industry PE
33.8
Reserves
₹-0.94
Free Cash Flow
₹3.41

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
GUJARAT TERCE LABORATORIES LTDNANANANA42.8
KMS Medisurgi LimitedNANANANA41.995.2
Chandra Bhagat Pharma LimitedNANANANA39.545.9

Peer Comparison Chart


About GUJARAT TERCE LABORATORIES

Gujarat Terce Laboratories Ltd, with Security Code 524314, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Gujarat Terce Laboratories Reports Financial Struggles Amid Declining Profitability in March 2025

(30 May 2025)
Gujarat Terce Laboratories has reported financial results for the quarter ending March 2025, revealing significant operational challenges.
Read more →

Earnings Today Alert: General Insurance Corp, Aurobindo Pharma, Sundaram Finance & 200+ Firms Set To Report Q4 Results

(29 May 2025)
The Indian stock market is poised for an action-packed day as over 200 companies are scheduled to announce their Q4 earnings.
Read more →

Gujarat Terce Laboratories reports standalone net loss of Rs 3.39 crore in the March 2025 quarter

(27 May 2025)
Sales rise 0.90% to Rs 12.32 crore. Net loss of Gujarat Terce Laboratories reported to Rs 3.39 crore in the quarter ended March 2025 as...
Read more →

Challani Capital standalone net profit rises 691.67% in the March 2025 quarter

(27 May 2025)
Sales rise 460.00% to Rs 1.12 crore. Net profit of Challani Capital rose 691.67% to Rs 0.95 crore in the quarter ended March 2025 as against...
Read more →

Phyto Chem (India) reports standalone net loss of Rs 1.16 crore in the March 2025 quarter

(27 May 2025)
Sales rise 224.44% to Rs 1.46 crore.
Read more →

Shakti Press reports standalone net loss of Rs 0.04 crore in the March 2025 quarter

(27 May 2025)
Sales rise 22.89% to Rs 4.08 crore.
Read more →